PMID: 9546921Jan 1, 1996Paper

The influence of apolipoprotein E on the interactions between normal human very low density lipoproteins and U937 human macrophages: heterogeneity among persons

Vascular Medicine
F M Sacks, G P Krukonis

Abstract

Apolipoprotein E (apo E) can mediate the cell binding of normal human very low density lipoproteins (VLDL). However, the extent to which apo E is involved in the cell binding and uptake of VLDL from different normolipidemic persons is not well defined. The VLDL (d < 1.006 g/l) of eight subjects were fractionated into VLDL with apo E and without apo E using a monoclonal antibody that binds to the LDL receptor recognition region of apo E. VLDL particles that expressed the 1D7 binding region of apo E comprised an average of 34% (range 7-51%) of the VLDL particles. Anti-apo E blocked an average of 43% (range 8-63%) of the binding of unfractionated VLDL to U937 cells. Anti-apo E blocked a similar proportion of binding to U937 cells of three VLDL subfractions of different density ranges (Sf20-60, Sf60-100, Sf100-400). The proportion of the VLDL particles that contained apo E correlated with the extent of uptake of the total VLDL by U937 cells, but not with stimulation by total VLDL of cholesterol ester formation. The binding to cells of VLDL without apo E varied by six-fold among persons, and caused most of the binding of the total VLDL of some subjects. Therefore, normolipidemic VLDL contains particles across its density range that ...Continue Reading

References

Dec 1, 1975·The Journal of Clinical Investigation·J P KaneR J Havel
May 15, 1976·International Journal of Cancer. Journal International Du Cancer·C Sundström, K Nilsson
Oct 1, 1977·The Journal of Clinical Investigation·F A Shelburne, S H Quarfordt
Nov 1, 1979·The Journal of Clinical Investigation·G SchonfeldS W Weidman
Jul 1, 1991·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·G AgnaniV Clavey
Nov 1, 1988·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·Y L MarcelR W Milne
Mar 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·S JaeckleR J Havel
Aug 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·R C KowalM S Brown
Aug 1, 1987·The Journal of Clinical Investigation·F KremplerF Sandhofer
Nov 1, 1988·The Journal of Clinical Investigation·S H GianturcoW A Bradley
Sep 1, 1988·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·S EisenbergT Vogel
Nov 1, 1986·The Journal of Clinical Investigation·E J SchaeferH B Brewer
Dec 5, 1986·Biochimica Et Biophysica Acta·A RubinsteinW V Brown
Jan 1, 1987·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·F M Sacks, J L Breslow
Feb 1, 1985·The Journal of Clinical Investigation·E S KrulG Schonfeld
Jan 1, 1983·Methods in Enzymology·J L GoldsteinM S Brown
Apr 1, 1982·Metabolism: Clinical and Experimental·P NestelN Fidge
Aug 1, 1983·Metabolism: Clinical and Experimental·P NestelN Fidge
Mar 1, 1980·The Journal of Clinical Investigation·F ShelburneS Quarfordt
Sep 28, 1995·The American Journal of Cardiology·W B Kannel

❮ Previous
Next ❯

Citations

Oct 7, 2005·Nature·Peter van den ElzenMichael B Brenner
Sep 15, 2001·Arteriosclerosis, Thrombosis, and Vascular Biology·K TomiyasuF M Sacks

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.